Исследование структуры коморбидности у пациентов с рассеянным склерозом с использованием валидированных опросников
https://doi.org/10.30629/2658-7947-2019-24-5-21-31
Аннотация
Об авторах
Н. А. Неофидов
Санкт-Петербургский городской центр рассеянного склероза и АИЗ (ГБОУ Городская клиническая больница №31); Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Минздрава России
Россия
Россия
Санкт-Петербург, 197110; Санкт-Петербург, 197022.
Г. С. Макшаков
Санкт-Петербургский городской центр рассеянного склероза и АИЗ (ГБОУ Городская клиническая больница №31); Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Минздрава России
Россия
Россия
Санкт-Петербург, 197110; Санкт-Петербург, 197022.
О. А. Лазовская
Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Минздрава России
Россия
Россия
Санкт-Петербург, 197022.
Н. А. Тотолян
Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Минздрава России
Россия
Россия
Санкт-Петербург, 197022.
М. В. Шумилина
Санкт-Петербургский городской центр рассеянного склероза и АИЗ (ГБОУ Городская клиническая больница №31); Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Минздрава России
Россия
Россия
Санкт-Петербург, 197110; Санкт-Петербург, 197022.
Е. П. Евдошенко
Санкт-Петербургский городской центр рассеянного склероза и АИЗ (ГБОУ Городская клиническая больница №31)
Россия
Россия
Санкт-Петербург, 197110.
Список литературы
1. Langer-Gould A., Popat R.A., Huang S.M., Cobb K., Fontoura P., Gould M.K., Nelson L.M. Clinical and Demographic Predictors of Long-term Disability in Patients With Relapsing-Remitting Multiple Sclerosis. Arch. Neurol. 2006;Dec;63(12):1686–91. https://doi.org/10.1001/archneur.63.12.1686
2. Marrie R.A., Rudick R., Horwitz R., Cutter G., Tyry T., Campagnolo D., and Vollmer T. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010;Mar 30;74(13):1041–1047. https://doi.org/10.1212/WNL.0b013e3181d6b125
3. Kirby S., Brown M.G., Murray T.J., et al. Progression of multiple sclerosis in patients with other autoimmune diseases. Mult. Scler. 2005;11:S28–S29.
4. Tourbah A., Clapin A., Gout O., et al. Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study. Arch. Neurol. 1998;55:517–521.
5. Marrie R.A. Comorbidity in Mulïple Sclerosis. Int. J. MS Care. 2016;Nov-Dec;18(6):271–272.
6. Valderas J.M., Starfield B., Sibbald B., Salisbury C., Roland M. Defining comorbidity: implications for understanding health and health services. Ann. Fam. Med. 2009;7(4):357–363. https://doi.org/10.1370/afm.983
7. Lash T.L., Mor V., Wieland D., Ferrucci L., Satariano W., Silliman R.A. Methodology, design, and analytic techniques to address measurement of comorbid disease. J. Gerontol. A Biol. Sci Med. Sci. 2007;Mar;62(3):281–5.
8. Myles Horton, Rudick R. A., Hara-Cleaver C., Marrie R.A. Validation of a Self-Report Comorbidity Questionnaire for Multiple Sclerosis. Neuroepidemiology 2010;35:83–90. https://doi.org/10.1159/000311013
9. Bayliss E.A., Ellis J.L., Steiner J.F. Subjective assessments of comorbidity correlate with quality of life health outcomes: initial validation of a comorbidity assessment instrument. Health Qual Life Outcomes. 2005;Sep 1;3:51. https://doi.org/10.1186/1477–7525–3–51.
10. Okura Y., Urban L.H., Mahoney D.W., Jacobsen S.J., Rodeheffer R.J. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol. 2004;Oct;57(10):1096–103. https://doi.org/10.1016/j.jclinepi.2004.04.005.
11. Kriegsman D.M., Penninx B.W., van Eijk J.T., Boeke A.J., Deeg D.J. Self-reports and general practitioner information on the presence of chronic diseases in community dwelling elderly.A study on the accuracy of patients’ self-reports and on determinants of inaccuracy. J Clin Epidemiol. 1996;Dec;49(12):1407–17.
12. Tisnado D.M., Adams J.L., Liu H., Damberg C.L., Chen W.P., Hu F.A., Carlisle D.M., Mangione C.M., Kahn K.L. What is the concordance between the medical record and patient self-report as data sources for ambulatory care? Med. Care. 2006;Feb;44(2):132–40.
13. Kang J.H., Chen Y.H., Lin H.C. Comorbidities amongst patients with multiple sclerosis: a population-based controlled study. Eur. J. Neurol. 2010;Sep;17(9):1215–9. https://doi.org/10.1111/j.1468–1331.2010.02971.x. Epub 2010 Feb 23.
14. Marrie R., Horwitz R,, Cutter G., Tyry T., Campagnolo D., Vollmer T. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler. 2008;Sep;14(8):1091–8. https://doi.org/10.1177/1352458508092263.
15. Landis J R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174.
16. Sim J., Wright C.C. The Kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys. Ther. 2005;85:257–268.
17. Provisional guidelines on standard international age classifications. Department of international economic and social affairs. Statistical office. United nations. 1982.
18. Katz J.N., Chang L.C., Sangha O., Fossel A.H., Bates D.W. Can comorbidity be measured by questionnaire rather than medical record review? Med. Care. 1996;34:73–84.
19. Bergmann M.M., Byers T., Freedman D.S., Mokdad A. Validity of self-reported diagnoses leading to hospitalization: a comparison of self-reports with hospital records in a prospective study of American adults. Am. J. Epidemiol. 1998;147:969–977.
20. Jadidi E., Mohammadi M., Moradi T. High risk of cardiovascular diseases after diagnosis of multiple sclerosis. Mult. Scler. 2013 Sep;19(10):1336–40. https://doi.org/10.1177/1352458513475833. Epub 2013 Jan 30.
21. Marrie R.A., Fisk J., Tremlett H., Wolfson C., Warren S., Blanchard J., Patten S. B., and for the CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis. Differing trends in the incidence of vascular comorbidity in MS and the general population. Neurol. Clin. Pract. 2016;Apr;6(2): 120–128. https://doi.org/10.1212/CPJ.0000000000000230
22. Barcellos L.F., Kamdar B.B., Ramsay P.P., DeLoa C., Lincoln R.R., Caillier S., Schmidt S., Haines J.L., Pericak-Vance M.A., Oksenberg J.R., Hauser S.L. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol. 2006;Nov;5(11):924–31.
23. Laroni A., Calabrese M., Perini P., Albergoni M.P., Ranzato F., Tiberio M., Battistin L., Gallo P. Multiple sclerosis and autoimmune diseases: epidemiology and HLA-DR association in North-east Italy. J Neurol. 2006;May;253(5):636–9. Epub 2006 Mar 6.
24. Deretzi G., Kountouras J., Koutlas E., Zavos C., Polyzos S., Rudolf J., Grigoriadis N., Gavalas E., Boziki M., Tsiptsios I. Familial prevalence of autoimmune disorders in multiple sclerosis in Northern Greece. Mult. Scler. 2010;Sep;16(9):1091–101. https://doi.org/10.1177/1352458510375708. Epub 2010 Jul 16.
25. Edwards L.J., Constantinescu C.S. A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult Scler. 2004;Oct;10(5):575–81.
26. Munteis E., Cano J.F., Flores J.A., Martinez-Rodriguez J.E., Miret M., Roquer J. Prevalence of autoimmune thyroid disorders in a Spanish multiple sclerosis cohort. Eur. J. Neurol. 2007;Sep;14(9):1048–52.
27. Laroni A., Calabrese M., Perini P., Albergoni M.P., Ranzato F., Tiberio M., Battistin L., Gallo P. Multiple sclerosis and autoimmune diseases: epidemiology and HLA-DR association in North-east Italy. J. Neurol. 2006;May;253(5):636–9. Epub 2006 Mar 6.
28. Shugaiv E., Tüzün E., Kürtüncü M., Kıyat-Atamer A., Çoban A., Akman-Demir G., Tugal-Tutkun I., Eraksoy M. Uveitis as a prognostic factor in multiple sclerosis. Mult Scler. 2015;Jan;21(1):105–7. https://doi.org/10.1177/1352458514539782. Epub 2014 Jun 16.
29. Гончарова З.А., Сизякина Л.П., Беловолова Р.А., Мегерян В.А. Коморбидная аутоиммунная патология у больных, получающих препараты, изменяющие течение рассеянного склероза. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2016;116(10):53–60. https://doi.org/10.17116/jnevro201611610253–60
30. Thormann A., Koch-Henriksen N., Laursen B., Sørensen P.S., Magyari M. Inverse comorbidity in multiple sclerosis: Findings in a complete nationwide cohort. Mult. Scler. Relat. Disord. 2016;Nov;10:181–186. https://doi.org/10.1016/j.msard.2016.10.008. Epub 2016 Oct 29.
31. Khurana S.R., Bamer A.M., Turner A.P., Wadhwani R.V., Bowen J.D., Leipertz S.L., et al. The prevalence of overweight and obesity in veterans with multiple sclerosis. Am. J. Phys. Med. Rehabil. 2009;88(2):83–91.
32. Marrie R.A., Patten S., Tremlett H., Svenson L.W., Wolfson C., Yu B.N., Elliott L., Profetto-McGrath J., Warren S., Leung S., Jette N., Bhan V., Fisk J.D. Chronic lung disease and multiple sclerosis: Incidence, prevalence, and temporal trends. Mult. Scler. Relat. Disord. 2016;Jul;8:86–92. https://doi.org/10.1016/j.msard.2016.05.009. Epub 2016 May 11.
33. Siegert R.J., Abernethy D.A. Depression in multiple sclerosis: a review. Journal of Neurology, Neurosurgery & Psychiatry. 2005;76:469–475.
34. Hartoonian N., Terrill A.L., Beier M.L., Turner A.P., Day M.A., Alschuler K.N. Predictors of anxiety in multiple sclerosis. Rehabil Psychol. 2015;60(1):91–98. https://doi.org/10.1037/rep0000019
35. Alsaadi T., Hammasi K.E., Shahrour T.M., et al. Depression and anxiety as determinants of health-related quality of life in patients with multiple sclerosis — United Arab Emirates. Neurol Int. 2017;9(4):7343. Published 2017;Dec 11. https://doi.org/10.4081/ni.2017.7343
36. Larochelle C., Uphaus T., Prat A., and Zipp F. Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology? Trends Neurosci. 2016;May;39(5):325–339.
37. J.S., Pryse W.E., Phillips M., Stefanelli M., and C. Co-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort. J. Autoimmune Dis. 2005;2:9. Published online 2005 Nov 9. https://doi.org/10.1186/1740–2557–2–9
38. Kreisler A., de Seze J., Stojkovic T., Delisse B., Combelles M., Vérier A., Hautecoeur P., Vermersch P. Multiple sclerosis, interferon beta and clinical thyroid dysfunction. Acta Neurol. Scand. 2003;Feb;107(2):154–7.
39. Palavra F., Marado D., Mascarenhas-Melo F., Sereno J., Teixeira-Lemos E., Nunes C.C., Gonçalves G., Teixeira F., Reis F. New markers of early cardiovascular risk in multiple sclerosis patients: oxidized-LDL correlates with clinical staging. Dis Markers. 2013;34(5):341–8. https://doi.org/10.3233/DMA-130979.
40. Tettey P., Simpson S. Jr, ,Taylor B., Blizzard L., Ponsonby A.L., Dwyer T., Kostner K., van der Mei I. An adverse lipid profile is associated with disability and progression in disability, in people with MS. Mult. Scler. 2014;Nov;20(13):1737–44. https://doi.org/10.1177/1352458514533162. Epub 2014 May 14.
41. Weinstock-Guttman B., Zivadinov R., Mahfooz N., Carl E., Drake A., Schneider J., Teter B., Hussein S., Mehta B., Weiskopf M., Durfee J., Bergsland N., Ramanathan M. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J. Neuroinflammation. 2011;Oct;4;8:127. https://doi.org/10.1186/1742–2094–8–127.
Рецензия
Для цитирования:
Неофидов Н.А., Макшаков Г.С., Лазовская О.А., Тотолян Н.А., Шумилина М.В., Евдошенко Е.П. Исследование структуры коморбидности у пациентов с рассеянным склерозом с использованием валидированных опросников. Российский неврологический журнал. 2019;24(5):21-31. https://doi.org/10.30629/2658-7947-2019-24-5-21-31
For citation:
Neofidov N.A., Makshkov G.S., Lazovskaya O.A., Totolyan N.A., Shumilina M.V., Evdoshenko E.P. The study of comboridity in patients with multiple sclerosis using validated sels-report questionnaires. Russian neurological journal. 2019;24(5):21-31. (In Russ.) https://doi.org/10.30629/2658-7947-2019-24-5-21-31
Просмотров: 1286
Послать статью по эл. почте 